Current FDA-approved pharmacotherapies for the treatment of post-traumatic stress
disorder (PTSD) are limited in number and efficacy. Recent evidence implicates the
nociceptin/orphanin FQ (NOP) receptor system in PTSD. Therefore, NOP antagonists may
have therapeutic potential for the treatment of PTSD. Here, we evaluate the efficacy
of NOP antagonists to remediate the effects of traumatic stress exposure using preclinical
rodent models of traumatic stress exposure and conditioned fear.
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Biological PsychiatryAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
Article info
Identification
Copyright
© 2019 Published by Elsevier Inc.
